Superpower Daily

Superpower Daily

Your reading space

Sign in
Stuart Russell Says AI Progress Should Wait for Safety ProofApple Releases macOS 27 With a Siri That Can Read Your ScreenBolt’s New Policies Permit Training Beyond Its Forge-Only PitchWaymo Sets 2027 Target for Driverless Tokyo Rides With GO and N...Texas Orders Water-Use Enforcement for Data Centers, Linking Di...Buildots Raises $130 Million to Scale AI Construction Tracking,...Stuart Russell Says AI Progress Should Wait for Safety ProofApple Releases macOS 27 With a Siri That Can Read Your ScreenBolt’s New Policies Permit Training Beyond Its Forge-Only PitchWaymo Sets 2027 Target for Driverless Tokyo Rides With GO and N...Texas Orders Water-Use Enforcement for Data Centers, Linking Di...Buildots Raises $130 Million to Scale AI Construction Tracking,...
Swipe

Corologic Raises Seed Funding to Validate AI That Restores Angiography Video

The South Korean startup wants to use AI-generated intermediate video frames to preserve procedural visibility while fewer X-ray images are taken. The next test is whether that approach holds up across clinical sites.

By 3 min read
Corologic Raises Seed Funding to Validate AI That Restores Angiography Video
Corologic Raises Seed Funding to Validate AI That Restores Angiography Video

Listen to this story

The audio brief

About 1:39
0:001:39
Read transcript
Corologic has raised undisclosed seed funding from Kakao Ventures to take AngioFilm from a technical demonstration into multicenter clinical testing and regulatory preparation. The South Korean startup is building AI that fills in missing moments in coronary angiography video, with the goal of preserving visibility while hospitals capture fewer X-ray images. During these cardiovascular procedures, X-ray fluoroscopy lets clinicians track blood vessels and medical devices in motion. Lowering the frame rate can reduce radiation exposure, but it can also leave doctors with less visual information. AngioFilm analyzes the frames immediately before and after a gap, tracks how vessels and devices are moving, and generates an estimated intermediate frame. The aim is a more continuous-looking view in real time—not a replacement for the angiography equipment. Corologic says the system can connect to existing hospital imaging setups and process data at the edge, inside the hospital rather than through a remote service. The new funding is earmarked for validation across multiple clinical sites, additional work with South Korea’s MFDS, preparation for a U.S. FDA 510(k) submission, and ISO 13485 quality certification. The company completed an MFDS filing or notification in August, but that is separate from proving the system clinically across sites, and AngioFilm does not yet have U.S. FDA clearance in the supplied reporting. The investment amount is undisclosed, and coverage conflicts over the second investor. The key question now is whether reconstructed frames remain reliable in real clinical workflows beyond a single technical demonstration.

Story brief

3 key points

Corologic is using Kakao Ventures’ undisclosed seed investment to move AngioFilm beyond a technical demonstration and into multicenter testing and regulatory preparation. The system generates intermediate frames from low-rate coronary angiography footage, aiming to preserve motion visibility while hospitals capture fewer X-ray images. It is designed for edge deployment with existing imaging setups, but the company...

  1. 01

    Funding is earmarked for multicenter clinical validation, South Korean MFDS work, FDA 510(k) preparation, and ISO 13485 certification.

  2. 02

    AngioFilm interpolates missing moments by analyzing adjacent frames and tracking vessel and device movement in real time.

  3. 03

    Corologic says the tool can integrate with existing hospital imaging systems and process data at the edge.

Corologic has raised undisclosed seed funding from Kakao Ventures for AngioFilm, an AI system meant to reconstruct a more continuous view from lower-frame-rate coronary angiography video. The financing shifts the young company’s task from a technical demonstration toward multicenter clinical validation and regulatory work for a tool designed to reduce X-ray exposure during cardiovascular procedures.

Coronary angiography and related cardiovascular interventions use X-ray fluoroscopy so clinicians can follow blood vessels and medical devices during a procedure. Taking fewer images can lower radiation exposure, but it also lowers the frame rate and can leave staff with less visual information to work from.

AngioFilm uses video frame interpolation: it analyzes the frames immediately before and after a missing moment, tracks changes in vessel and device position, then estimates and generates an intermediate image. Corologic’s aim is to turn low-frame-rate footage into what appears to be higher-frame-rate video in real time, allowing clinicians to follow movement more continuously while fewer X-ray images are captured.

The startup is not proposing that hospitals replace angiography machines. It says AngioFilm can be added to an existing procedure environment, integrated with hospital imaging systems and processed at the edge, meaning image processing happens in the hospital rather than being sent elsewhere for real-time handling.

What the seed money is intended to support

  • Multicenter clinical validation of AngioFilm.
  • Further regulatory work with South Korea’s Ministry of Food and Drug Safety.
  • A planned U.S. Food and Drug Administration 510(k) clearance effort and ISO 13485 quality certification.

Corologic completed a medical-device filing or notification with South Korea’s Ministry of Food and Drug Safety in August, according to the two reports. That step is distinct from the broader validation and approval work it now plans to pursue; the company has not yet established in the supplied reporting that AngioFilm has completed multicenter clinical validation or received U.S. FDA clearance.

Corologic was founded in May 2026 by a team led by Sihyuk Kang of Seoul National University Bundang Hospital’s cardiology division. It demonstrated AngioFilm and presented related research at EuroPCR in May. The company now has capital to test whether its reconstructed frames can support real clinical workflows across sites, while its equipment-independent installation model is meant to reduce the practical friction of adoption.

Both accounts identify Kakao Ventures as an investor and say the amount was not disclosed. They differ on the other participant: Seoul Economic Daily names SNU Holdings, while WOWTALE names Seoul Techno Holdings. Corologic’s announced financing is the central fact; the co-investor identity is not consistent across the supplied coverage.

Sources

  1. en.sedaily.comCardiovascular AI Startup Corologic Raises Seed Funding From Kakao Ventures
  2. en.wowtale.netCardiovascular Imaging AI Startup Corologic Raises Seed Funding from Kakao Ventures and Seoul Techno Holdings - WOWTALE

Loading discussion...

Related coverage

Continue reading